Short answer
IDEAYA Biosciences, Inc. (IDYA) filed an 8-K current report with the SEC on April 9, 2026 reporting Item 8.01 (Other Events). Clinical collaboration with AstraZeneca evaluating IDE849 plus Imfinzi in extensive-stage small cell lung cancer.
IDEAYA Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Clinical collaboration with AstraZeneca evaluating IDE849 plus Imfinzi in extensive-stage small cell lung cancer
- IDEAYA sponsors the combination trial; AstraZeneca supplies Imfinzi, reducing trial drug-supply burden
- IDE849 advancing in global Phase 1 across SCLC, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma
- Potential validation from AstraZeneca involvement, but clinical efficacy, safety, enrollment, and regulatory outcomes remain uncertain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IDEAYA Biosciences, Inc. 8-K filings
Get the next IDYA 8-K as it lands
Follow IDYA for push alerts, or ask the research agent what this filing means.